QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, X. Articles by Smith, B. J. Search for Related Content PubMed PubMed Citation Articles by Liu, X. Articles by Smith, B. J.

DEVELOPMENT OF A COMPUTATIONAL APPROACH TO PREDICT BLOOD-BRAIN BARRIER PERMEABILITY

Department of Pharmacokinetics, Dynamics and Metabolism (X.L., C.C., B.J.S.) and Department of Exploratory Medicinal Sciences (M.T., R.S.K.), Groton Laboratories, Pfizer Global Research and Development, Groton, Connecticut

The objectives of this study were to generate a data set of blood-brain barrier (BBB) permeability values for drug-like compounds and to develop a computational model to predict BBB permeability from structure. The BBB permeability, expressed as permeability-surface area product (PS, quantified as logPS), was determined for 28 structurally diverse drug-like compounds using the in situ rat brain perfusion technique. A linear model containing three descriptors, logD, van der Waals surface area of basic atoms, and polar surface area, was developed based on 23 compounds in our data set, where the penetration across the BBB was assumed to occur primarily by passive diffusion. The correlation coefficient (R²) and standard deviation (S.D.) of the model-predicted logPS against the observed are 0.74 and 0.50, respectively. If an outlier was removed from the training data set, the R² and S.D. were 0.80 and 0.44, respectively. This new model was tested in two literature data sets, resulting in an R² of 0.77 to 0.94 and a S.D. of 0.38 to 0.51. For comparison, four literature models, logP, logD, log(D · MW^–0.5), and linear free energy relationship, were tested using the set of 23 compounds primarily crossing the BBB by passive diffusion, resulting in an R² of 0.33 to 0.61 and a S.D. of 0.59 to 0.76. In summary, we have generated the largest PS data set and developed a robust three-descriptor model that can quantitatively predict BBB permeability. This model may be used in a drug discovery setting to predict the BBB permeability of new chemical entities.

This article has been cited by other articles:

				K. Shintaku, S. Hori, M. Tsujimoto, H. Nagata, S. Satoh, K. Tsukimori, H. Nakano, T. Fujii, Y. Taketani, H. Ohtani, et al. Transplacental Pharmacokinetics of Diclofenac in Perfused Human Placenta Drug Metab. Dispos., May 1, 2009; 37(5): 962 - 968. [Abstract] [Full Text] [PDF]

				R. Zhao, J. C. Kalvass, S. B. Yanni, A. S. Bridges, and G. M. Pollack Fexofenadine Brain Exposure and the Influence of Blood-Brain Barrier P-Glycoprotein After Fexofenadine and Terfenadine Administration Drug Metab. Dispos., March 1, 2009; 37(3): 529 - 535. [Abstract] [Full Text] [PDF]

				X. Liu, C. Chen, and B. J. Smith Progress in Brain Penetration Evaluation in Drug Discovery and Development J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 349 - 356. [Abstract] [Full Text] [PDF]

				S. Kiem and J. J. Schentag Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid Antimicrob. Agents Chemother., January 1, 2008; 52(1): 24 - 36. [Full Text] [PDF]

				S. Lemaire, F. Van Bambeke, M.-P. Mingeot-Leclercq, and P. M. Tulkens Modulation of the Cellular Accumulation and Intracellular Activity of Daptomycin towards Phagocytized Staphylococcus aureus by the P-Glycoprotein (MDR1) Efflux Transporter in Human THP-1 Macrophages and Madin-Darby Canine Kidney Cells Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2748 - 2757. [Abstract] [Full Text] [PDF]

				S. G. Summerfield, K. Read, D. J. Begley, T. Obradovic, I. J. Hidalgo, S. Coggon, A. V. Lewis, R. A. Porter, and P. Jeffrey Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 205 - 213. [Abstract] [Full Text] [PDF]

				Y. Zhang, C. S. W. Li, Y. Ye, K. Johnson, J. Poe, S. Johnson, W. Bobrowski, R. Garrido, and C. Madhu Porcine Brain Microvessel Endothelial Cells as an in Vitro Model to Predict in Vivo Blood-Brain Barrier Permeability Drug Metab. Dispos., November 1, 2006; 34(11): 1935 - 1943. [Abstract] [Full Text] [PDF]

				X. Liu, B. J. Smith, C. Chen, E. Callegari, S. L. Becker, X. Chen, J. Cianfrogna, A. C. Doran, S. D. Doran, J. P. Gibbs, et al. Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration Drug Metab. Dispos., September 1, 2006; 34(9): 1443 - 1447. [Abstract] [Full Text] [PDF]

				J. T. Goodwin and D. E. Clark In Silico Predictions of Blood-Brain Barrier Penetration: Considerations to "Keep in Mind" J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 477 - 483. [Abstract] [Full Text] [PDF]

				X. Liu, B. J. Smith, C. Chen, E. Callegari, S. L. Becker, X. Chen, J. Cianfrogna, A. C. Doran, S. D. Doran, J. P. Gibbs, et al. Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1254 - 1262. [Abstract] [Full Text] [PDF]